Which Patients With Early-Stage Triple-Negative Breast Cancer Should Receive a Platinum?

William M. Sikov, MD

  H&O  What forms of cancer are typically treated with platinum agents? WS  Platinum analogues are used to treat a wide range of solid tumors, including […]

The Microbiome: A Basis for Novel Immunomodulation in Mice and Men

Hassane M. Zarour, MD

  H&O  Why does immunotherapy work better in some patients with melanoma than in others? HZ  We are still unsure about that, but we are working […]

Immunotherapy in Urothelial Cancer, Part 2: Adjuvant, Neoadjuvant, and Adjunctive Treatment

Steven S. Yu, MD, Leslie K. Ballas, MD, Eila C. Skinner, MD, Tanya B. Dorff, MD, Sarmad Sadeghi, MD, PhD, and David I. Quinn, MBBS (Hons), PhD, FRACP, FACP

  Abstract:  Urothelial cancer, which is predominantly seen in men, is common throughout the world. Most disease presents as non–muscle invasive bladder cancer (NMIBC), with cancer […]

Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia: Progress in a New Cancer Subtype

Julia Wells, PhD, Nitin Jain, MD, and Marina Konopleva, MD, PhD

  Abstract: Philadelphia chromosome–like (Ph-like) acute lymphoblastic leukemia (ALL) is a newly described, high-risk subtype of B-cell ALL. It is characterized by a gene expression profile […]

New Insights Into Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplant

Michael Boeckh, MD, PhD

  H&O  How common is CMV infection among patients undergoing allogeneic hematopoietic stem cell transplant? MB Cytomegalovirus (CMV) reactivation occurs in approximately 50% to 70% of […]

View More Issues